PALO
ALTO, Calif., April 25,
2024 /PRNewswire/ -- Orchid, a reproductive
technology company offering the world's only commercially available
whole genome embryo screening, today announced Dr. Amber Cooper, Dr. Roohi Jeelani, and
Jerry Lanchbury, Ph.D as new members
joining their Medical and Scientific Advisory Board. The boards
support Orchid's mission to provide parents with more genetic
information than ever before, enabling them to mitigate their
child's risk for genetic forms of neurodevelopmental disorders,
pediatric cancers, and birth defects that were previously
impossible to detect in embryos.
Orchid Welcomes Distinguished Clinical and
Genetics Leaders to its Advisory Boards
"As a clinician dedicated to providing the highest standard of
care, I am thrilled about Orchid's whole genome embryo screening
being available to patients," said Dr. Roohi Jeelani, a double board certified
Reproductive Endocrinologist and Infertility Specialist (REI).
"This technology empowers prospective parents by providing
comprehensive insights into their embryos' genetics, allowing for
informed decisions that can contribute to a healthier start for
their future child. I believe this will become a standard part in
many families' IVF journeys."
"Orchid is empowering parents like never before. Their whole
genome embryo reports screen for hundreds of conditions, and shifts
us from just reacting to medical issues to proactively addressing
potential concerns right from the start," said Dr. Amber Cooper. "I am thrilled to advise this team
as they help future generations of healthier babies be born."
"It's exciting that parents have the opportunity to make choices
about whether they do or don't pass mutations onto their children
through embryo screening. They are able to target a healthy life
for their child," said Jerry
Lanchbury, previous Chief Scientific advisor of Myriad
Genetics.
"We could not be more honored to have the support and guidance
of these integral figures in reproductive medicine and genetics,"
said Noor Siddiqui, founder and CEO
of Orchid. "We look forward to bringing Orchid to more parents, and
providing them with critical genomic information to give their
future children a healthy start to life."
They will join Lusine Aghajanova, MD, Ph.D, Barry Behr, Ph.D, Jacques Cohen, Ph.D, Jonathan Kort, MD, and Jan Liphardt, Ph.D as part of Orchid's existing
advisory board.
Orchid's whole genome embryo report offers the most data for
individuals going through IVF interested in mitigating the maximum
amount of genetic risk. Orchid whole genome embryo reports are
available nationwide at IVF centers of excellence in San Francisco, Los
Angeles, Chicago,
Austin, Atlanta, Dallas, Denver, Detroit, Miami, Milwaukee, Minneapolis, Philadelphia, Princeton, St.
Louis, and Washington,
D.C.
New advisor profiles
Amber
R. Cooper, MD, serves as the Chief Medical
Officer-Genomics and Laboratory Sciences and Medical and IVF
Practice Director, St. Louis. Dr.
Cooper is board certified in both Obstetrics and Gynecology and
Reproductive Endocrinology and Infertility, and completed her
residency and fellowship at Washington
University in St. Louis.
During her years of practice, Dr. Cooper has been named one of the
Best Doctors in America nine times since 2013, and has authored
articles for several medical journals and textbooks.
Dr. Roohi Jeelani, MD,
FACOG, is a double board certified Reproductive Endocrinologist
and Infertility Specialist (REI), practicing in Chicago and Detroit.. A graduate of Ross University School
of Medicine, she completed both her residency in Obstetrics and
Gynecology and her fellowship in Reproductive Endocrinology and
Infertility at Wayne State University –
Detroit Medical Center. During her medical training, Dr. Jeelani
received numerous awards in the areas of fetal medicine and
reproductive medicine. In addition, she has authored a variety of
publications and book chapters in well known journals highlighting
cutting-edge REI advancement and has presented at
national/international conferences and symposiums focused on
advancements in women's health.
Jerry Lanchbury, Ph.D,
served as the Chief Scientific Officer at Myriad Genetics, leading
teams responsible for major molecular diagnostic innovations. Dr.
Lanchbury is a highly respected expert in immunogenetics with more
than 100 reviewed research journal publications. Dr. Lanchbury
earned his doctorate in Human Population Genetics from the
University of Newcastle upon Tyne
and subsequently held a number of tenured faculty positions at the
University of London.
About Orchid
Orchid is a reproductive technology
company on a mission to extend the healthspan of the next
generation. Orchid offers prospective parents a clear and
comprehensive understanding of their potential child's genetic
health.
In 2023, Orchid launched the world's first commercially
available 30x whole genome sequencing reports for embryos created
through IVF. Reading over 99% of an embryo's genome —significantly
surpassing the industry standard of 0.25%. Orchid's reports obtain
over 100 times the data, enabling the detection of conditions
previously undetectable in embryos and providing superior results
for traditional screens.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/orchid-welcomes-distinguished-clinical-and-genetics-leaders-to-its-advisory-boards-302127555.html
SOURCE ORCHID